Real-world study determining the safety and efficacy of teclistamab in R/R multiple myeloma

Real-world efficacy & safety of teclistamab in patients with heavily pretreated R/R multiple myelomaПодробнее

Real-world efficacy & safety of teclistamab in patients with BCMA-pretreated R/R multiple myelomaПодробнее

Safety and efficacy of teclistamab in patients with triple-class exposed R/R myelomaПодробнее

Real-world safety and efficacy of cilta-cel in R/R multiple myelomaПодробнее

Real-world outcomes of teclistamab for R/R multiple myelomaПодробнее

Real-World Safety and Efficacy of Teclistamab | Hamza Hashmi | ASH 2023Подробнее

Safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatambПодробнее

Clinical benefit of teclistamab vs real-world physician’s choice for R/R multiple myelomaПодробнее

Comparative efficacy of teclistamab vs pom+dex in triple-class exposed R/R myelomaПодробнее

Updated Efficacy/Safety Results of MajesTEC-1 (Teclistamab) at ASCO 2022Подробнее

Real-world outcomes of teclistamab treatment in R/R multiple myelomaПодробнее

MajesTEC-2 update: teclistamab plus lenalidomide in R/R multiple myelomaПодробнее

Real World Teclistamab Results for Relapsed Refractory Myeloma Patients | Meera Mohan, MD | ASH 2023Подробнее

Real World Experiences of Patients Treated with Teclistamab | Shonali Midha, MD | IMS 2023Подробнее

Efficacy of Teclistimab versus current treatments in patients with triple-class exposed RR myelomaПодробнее

Evaluating Teclistamab in Relapsed and/or Refractory Multiple MyelomaПодробнее

Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 ResultsПодробнее

What are the real-world outcomes following treatment with teclistamab in RRMM?Подробнее

Teclistamab for multiple myeloma in US hospitals: real-world data analysisПодробнее